SAN-711 is under clinical development by Saniona and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SAN-711’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SAN-711 overview

SAN-711 is under development for the treatment of rare neuropathic pain disorders such as burning mouth syndrome, migraine and epilepsy. It is a new chemical entity that acts by targeting GABAA alpha 2 and alpha 3 receptors. It is administered through oral route in the form of liquid.

It was also under development for rare intractable neuropathic itch conditions such as prurigo nodularis, brachioradial pruritus.

Saniona overview

Saniona is a biopharmaceutical company that discovers, develops, and delivers treatments for rare diseases. It is investigating Tesomet, a combination of tesofensine and metoprolol against hypothalamic obesity and Prader-Willi syndrome. The company is also evaluating SAN711, a positive allosteric modulator of GABAA a3 receptors to treat rare neuropathic disorders; and SAN903, an inhibitor of calcium-activated potassium ion channel (KCa3.1) targeting rare inflammatory and fibrotic disorders. Saniona utilizes its proprietary ion channel drug discovery engine anchored by IONBASE to discover its products. It works in partnership with Productos Medix SA de CV, Novartis AG, Boehringer Ingelheim International GmbH, and other pharmaceutical companies. It has an operational presence in Denmark and the US. Saniona is headquartered in Ballerup, Denmark.

For a complete picture of SAN-711’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.